In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remissionDecember 5, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
FLT3 inhibitor moves forward in newly diagnosed AMLDecember 4, 2018Leukemia, Myelodysplasia, Transplantation
Beat AML trial delivers genomic results in 7 daysDecember 2, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Gut bacteria influence HCT outcomesDecember 2, 2018Leukemia, Myelodysplasia, TransplantationImmuno-oncology
ELIANA update: Tisagenlecleucel responses durable in r/r B-cell ALLDecember 2, 2018Leukemia, Myelodysplasia, Transplantation
Ibrutinib outperforms bendamustine and rituximab in older CLL patientsDecember 2, 2018Leukemia, Myelodysplasia, Transplantation
MEDALIST: Erythroid maturation agent reduced transfusion burden in MDSDecember 1, 2018Leukemia, Myelodysplasia, Transplantation
Stem cell transplant after CAR T cells may reduce B-ALL relapse riskDecember 1, 2018Leukemia, Myelodysplasia, TransplantationPediatrics
FDA warns of serious side effect of AML treatmentNovember 30, 2018Leukemia, Myelodysplasia, Transplantation
FDA approves gilteritinib for AML with FLT3 mutationNovember 28, 2018Leukemia, Myelodysplasia, Transplantation
Venetoclax gets accelerated approval in older AML patientsNovember 21, 2018Leukemia, Myelodysplasia, Transplantation
Azacitidine-nivolumab combo 'encouraging' in AMLNovember 14, 2018Leukemia, Myelodysplasia, TransplantationImmuno-oncology
Consider treatment, testing when CLL symptoms emergeNovember 13, 2018Leukemia, Myelodysplasia, Transplantation
Prognostic features could improve ALL outcomesNovember 13, 2018Leukemia, Myelodysplasia, Transplantation
